FIGNL2 Inhibitors
Chemical inhibitors of FIGNL2 disrupt the protein's role in DNA repair through various mechanisms. Etoposide, a topoisomerase II inhibitor, creates a barrier for FIGNL2 by inducing DNA strand breaks that the protein typically repairs. Similarly, mitoxantrone and amsacrine also target topoisomerase II, leading to an accumulation of DNA strand breaks and impeding FIGNL2's ability to mediate repair. Teniposide compounds the problem, binding to the topoisomerase II-DNA complex and increasing the number of breaks in the DNA strands. These topoisomerase inhibitors collectively contribute to a surge in damaged DNA that challenges FIGNL2's repair capacity. Doxorubicin and daunorubicin, both intercalating agents, associate with topoisomerase II as well, creating additional breaks in DNA strands that FIGNL2 is tasked to repair. The overload of DNA damage from these agents can overwhelm the repair mechanisms, thus inhibiting the protein's function.
The DNA intercalation method is further employed by idarubicin and epirubicin, which exacerbate DNA damage. Pixantrone continues this trend, adding to the DNA insults that FIGNL2 must address. Actinomycin D's mechanism of binding to the transcription initiation complex and preventing RNA polymerase from progressing also leads to DNA damage that FIGNL2 would typically repair. Mitomycin C introduces an alternative form of DNA lesion through cross-linking, which presents a significant challenge for FIGNL2's role in DNA repair. The cumulative effect of these chemical inhibitors creates a substantial burden on FIGNL2's ability to maintain genomic stability by impeding its essential function in the DNA repair process.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide inhibits topoisomerase II, an enzyme that relieves torsional stress in DNA during replication. FIGNL2 is involved in DNA repair and homologous recombination processes that can be reliant on proper DNA unwinding and replication. Etoposide-induced topoisomerase II inhibition leads to DNA damage and can obstruct FIGNL2-mediated repair activities. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin targets topoisomerase I, preventing DNA re-ligation and causing DNA damage. As FIGNL2 functions in the repair of DNA, the stabilization of topoisomerase I-DNA cleavable complexes by camptothecin leads to an increase in DNA breaks, thus inhibiting the DNA repair function where FIGNL2 is involved. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks. This action can compromise the DNA repair pathways, including those facilitated by FIGNL2, by increasing the substrate (damaged DNA) that FIGNL2 must process, effectively overwhelming its repair capacity. | ||||||
Amsacrine hydrochloride | 54301-15-4 | sc-214540 | 10 mg | $232.00 | ||
Amsacrine is a topoisomerase II inhibitor that interferes with the enzyme's DNA strand passage step, leading to an accumulation of DNA strand breaks. The increased DNA damage would inhibit FIGNL2's ability to effectively participate in DNA repair processes due to the excess of damaged substrates. | ||||||
Teniposide | 29767-20-2 | sc-204910 sc-204910A | 25 mg 100 mg | $73.00 $235.00 | 6 | |
Teniposide binds to topoisomerase II after it cleaves the DNA, preventing the religation of the DNA strands and leading to increased DNA breaks. The inhibition of topoisomerase II increases the workload on DNA repair proteins like FIGNL2, thereby inhibiting their function by causing a backlog of repair processes. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin intercalates into DNA and associates with topoisomerase II, leading to breaks in DNA strands. This can inhibit the function of FIGNL2 by increasing the demand on the DNA repair systems, potentially overwhelming the capacity of FIGNL2 to mediate repair processes. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA at the transcription initiation complex and prevents elongation by RNA polymerase. This binding can also cause DNA damage that requires repair, and the excess damage could inhibit FIGNL2's role by overtaxing the DNA repair machinery that FIGNL2 is a part of. | ||||||
Daunorubicin hydrochloride | 23541-50-6 | sc-200921 sc-200921A sc-200921B sc-200921C | 10 mg 50 mg 250 mg 1 g | $105.00 $438.00 $837.00 $1569.00 | 4 | |
Daunorubicin intercalates into DNA and blocks topoisomerase II, leading to DNA breaks. This increased DNA damage inhibits the repair function of FIGNL2 by increasing the number of repair events required, thus hindering its efficiency and capacity to act. | ||||||
Idarubicin | 58957-92-9 | sc-507346 | 10 mg | $180.00 | ||
Idarubicin, another DNA intercalating agent and topoisomerase II inhibitor, causes DNA breaks that can overwhelm the DNA repair machinery, including FIGNL2, thus inhibiting the protein's repair activities. | ||||||
Pixantrone | 144510-96-3 | sc-481154 | 5 mg | $615.00 | ||
Pixantrone interferes with DNA replication and transcription by intercalating into DNA and inhibiting topoisomerase II. The resulting elevated DNA damage can inhibit FIGNL2 function as the repair machinery, including FIGNL2, becomes inundated with damaged DNA. | ||||||